HI HB2384

Excludes apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, naloxegol, naloxone, and naltrexone (and their salts) from Schedule II controlled substances classification for opioids and opiates.

Allows practitioners to prescribe Schedule III, IV, or V narcotic drugs approved by the FDA specifically for maintenance or detoxification treatment if they comply with federal regulations under 21 CFR 1301.28 and state registration requirements.

Permits practitioners registered separately with the Drug Enforcement Administration as narcotic treatment programs to administer or dispense (but not prescribe) any schedule narcotic drug for maintenance or detoxification treatment.

Allows non-registered physicians to administer (but not prescribe) narcotic drugs to relieve acute withdrawal symptoms for up to three days while arranging referral for treatment, with no more than one day's medication provided at a time.

Clarifies that narcotic drug administration or dispensing by hospital staff for maintenance, detoxification, or pain management incidental to medical or surgical treatment remains permissible and is not subject to the new prescription restrictions.